Clinical Trials
12 trialsNCT04670679 2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
NCT02989636 2026-01-06
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT01407198 2025-12-19
Nilotinib With Radiation for High Risk Chordoma
Massachusetts General Hospital
Phase 1 Completed
NCT02936102 2025-11-14
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT04246671 2025-03-03
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
Bavarian Nordic
Phase 1 Completed
NCT05355753 2024-12-17
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
C4 Therapeutics, Inc.
Phase 1 Terminated
NCT03955042 2023-03-07
Pemetrexed for the Treatment of Chordoma
Saint John's Cancer Institute
Phase 1 Completed
NCT01924689 2019-09-09
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
BioMed Valley Discoveries, Inc
Phase 1 Completed
NCT01682746 2019-02-25
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Medical College of Wisconsin
Phase 1 Completed
NCT00003926 2017-11-29
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT01175109 2012-12-27
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
University of Virginia
Phase 1 Unknown